Analysis of frailty status and associated factors in elderly patients with benign prostatic hyperplasia

Background: To explore the current status of frailty in elderly patients with benign prostatic hyperplasia (BPH) and analyze the influencing factors. Methods: This study used a cross-sectional design, in which we selected 220 inpatients aged >60 years who were admitted to the Departments of Geriatrics and Urology and diagnosed with BPH. Participants were categorized into a non-frail (normal) group (n = 83) and a frail group (n = 137) according to the Tilburg Frailty Indicator (TFI). General characteristics were collected, and the Mini Nutritional Assessment-Short Form (MNA-SF), Montreal Cognitive Assessment (MoCA), and a reverse questionnaire survey were administered. Univariate analysis, correlation analysis, and binary logistic regression were conducted to identify factors associated with frailty in elderly BPH patients. Results: Univariate analysis showed that the main factors influencing frailty in elderly BPH patients were age, International Prostate Symptom Score (IPSS), disease duration, alcohol consumption, body mass index (BMI), personal monthly income, number of chronic diseases, MNA-SF score, and MoCA score (all p < 0.05). The total TFI score was negatively correlated with both MNA-SF (r = −0.297) and MoCA (r = −0.209), and these correlations were statistically significant (p < 0.05). In the binary logistic regression analysis, IPSS score, disease duration, alcohol consumption, number of chronic diseases, and MNA-SF score emerged as the main factors associated with frailty (p < 0.05). Conclusions: Older adults with BPH often have a long disease course, may consume alcohol, and frequently present with multiple chronic conditions. For them, higher IPSS scores and lower MNA-SF scores are associated with a greater likelihood of frailty, indicating that nutritional status and symptom burden warrant particular attention. Thus, targeted assessment and interventions could be implemented to reduce frailty risk in this population.

Benign prostatic hyperplasia; Frailty influencing factors; Elderly patients

[1] Chen Y, Li Y, Li L, Wang M, Lv Z, Liu S, et al. Global, regional, and national lifetime risks of developing benign prostatic hyperplasia in men aged over 40: a population-based cross-sectional study from 1990 to 2021. Tropical Medicine and Health. 2025; 53: 93.

[2] Duan D, Kim LJ, Jun JC, Polotsky VY. Connecting insufficient sleep and insomnia with metabolic dysfunction. Annals of the New York Academy of Sciences. 2023; 1519: 94–117.

[3] Hjelholt TJ, Lietzen LW, Kongensgaard R, Bech JK, Azuz S, Hjelholt AJ, et al. Optimizing prevention of recurrent urinary tract infections in older patients with frailty. Drugs Aging. 2025; 42: 807–820.

[4] Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004; 63: 709–715.

[5] Sobrinho ACDS, Da Silva Rodrigues G, Gomes GAO, Bueno Júnior CR. Movement-based interventions in pre-frail and frail older adults: an integrative review of clinical, digital, and implementation evidence. Clinical Interventions in Aging. 2026; 21: 235–255.

[6] Wang CC, Xie H, Cai WW. Analysis on the frailty of the elderly in community and its influencing factors. Chinese Journal of General Practice. 2021; 19: 625–627. (In Chinese)

[7] Wong CK, Choi EP, Chan SW, Tsu JH, Fan CW, Chu PS, et al. Use of the International Prostate Symptom Score (IPSS) in Chinese male patients with benign prostatic hyperplasia. The Aging Male. 2017; 20: 241–249.

[8] Rubenstein LZ, Harker JO, Salvá A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). The Journals of Gerontology: Series A. 2001; 56: M366–M372.

[9] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2005; 53: 695–699.

[10] Bauer SR, Parker-Autry C, Lu K, Cummings SR, Hepple RT, Scherzer R, et al. Skeletal muscle health, physical performance, and lower urinary tract symptoms in older adults: the study of muscle, mobility, and aging. The Journals of Gerontology: Series A. 2024; 79: glad218.

[11] Baug S, Beisland C, Moen CA, Odland P, Blomquist J, Juliebø-Jones P. Transurethral resection of the prostate in the extreme elderly (≥ 85 years): treatment success, morbidity and survival. World Journal of Urology. 2025; 43: 572.

[12] Kyoda Y, Shibamori K, Shindo T, Maehana T, Hashimoto K, Kobayashi K, et al. Intrinsic and extrinsic factors causing hyperplasia of the prostate. International Journal of Urology. 2024; 31: 705–717.

[13] McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England Journal of Medicine. 2003; 349: 2387–2398.

[14] Nik-Ahd F, Zhao S, Boscardin WJ, Wang L, Covinsky K, Suskind AM. Development of the UroARC surgical calculator: a novel risk calculator for older adults undergoing surgery for bladder outlet obstruction. The Journal of Urology. 2024; 212: 451–460.

[15] Kuno T, Tamura K, Fukuhara H, Fukata S, Ashida S, Karashima T, et al. Tadalafil 5 mg once daily improved each IPSS subscore, QOL, and nocturia in elderly BPH patients over 70 years old in a real-world clinical setting. Urologia Internationalis. 2022; 106: 1005–1011.

[16] Ali SR, Nkembo AT, Tipparaju SM, Ashraf M, Xuan W. Sarcopenia: recent advances for detection, progression, and metabolic alterations along with therapeutic targets. Canadian Journal of Physiology and Pharmacology. 2024; 102: 697–708.

[17] Ouyang C, Zhou L, Liu J, Wang L, Lu Y. Benign prostatic hyperplasia increases long-term chronic kidney disease risk. Mayo Clinic Proceedings. 2025; 100: 790–800.

[18] Kaiser MJ, Bauer JM, Ramsch C, Uter W, Guigoz Y, Cederholm T, et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): a practical tool for identification of nutritional status. Journal of Nutrition, Health and Aging. 2009; 13: 782–788.

[19] Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men: a review. JAMA. 2025; 334: 809–821.

[20] Merrill RM, Song D, Ashton MK. Comparing the strength of associations between male genital problems and mental illnesses and sleep disorders. American Journal of Men’s Health. 2024; 18: 15579883241228243.

[21] Jiang W, Liu H, Tao X, Xu Q, Min J, Luo Y, et al. Research on the current status and risk prediction model of oral frailty among the elderly in Anhui Province. Journal of Practical Stomatology. 2025; 41: 261–266.

[22] Hu Z, Tian Y, Hu X. Associations between the risk of LUTS/BPH and the number and class of chronic diseases among middle-aged and elder men. Scientific Reports. 2025; 15: 14965.

[23] He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer and Prostatic Diseases. 2016; 19: 7–13.

[24] Wang Z, Dong YQ, Kumari S, Murphy D, Merchant RA. The impact of frailty, activity of daily living, and malnutrition on mortality in older adults with cognitive impairment and dementia. Nutrients. 2025; 17: 2612.